drugset / Trial / NCT02831231

Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium

NCT02831231

Phase 1 Completed 70 enrolled Karuna Therapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is intended to determine whether the addition of trospium chloride to xanomeline tartrate will ameliorate the peripheral cholinergic side effects that have been previously experienced with xanomeline tartrate when administered alone.

Timeline

Start
2016-09-07
Primary completion
2016-10-28
Completion
2016-10-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Trospium Small molecule 20 mg
Subject Xanomeline Small molecule 75 mg

Indications